Annex IV

Conditions of the marketing authorisations

National Competent Authorities shall ensure that the following conditions are fulfilled by the MAHs of aprotinin containing medicinal products:

1. Marketing authorisation holders of aprotinin containing medicinal products shall submit to the national competent authorities, further to the issuing of the Commission Decision and prior to re-launch of the medicinal product to the European market, an update of the risk management plan (RMP) referring to the agreed products' safety concerns as described in the assessment report of the referral procedure and their risk minimisation which includes a direct healthcare professional communication. This RMP shall follow the EU RMP template and shall include the measures to assess the effectiveness of the risk minimisation.

2. Marketing authorisation holders shall conduct a registry, in order to monitor the pattern of use of aprotinin. The registry shall record utilisation information on patients at cardiac surgery centres exposed to aprotinin in participating countries. It shall thus be set up in advance of placing the product on the market. The MAH shall take due account of the draft protocol and comments received during assessment. The registry's protocol shall be submitted to the national competent authorities within 2 months of Commission Decision. Updates on the registry will be submitted to national competent authorities with periodic safety update reports (PSURs).

3. A restricted distribution of aprotinin with the above mentioned registry, with aprotinin available only to centres that perform cardiac surgery on cardio-pulmonary bypass and that commit to participate in the registry.